Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-11-21
1998-06-09
Jarvis, William R.A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
057634351
ABSTRACT:
This invention concerns a method of delivering UDCA to a mammal to inhibit or treat a disorder, which includes administering a sulfate of UDCA to the mammal in an amount sufficient to inhibit or treat the disorder. For example, a UDCA sulfate may be used to advantage in inhibiting or treating an inflammatory condition of the gastrointestinal tract, such as colon cancer, rectum cancer, a neoplasm of the colon, a neoplasm of the rectum, carcinogenesis of the colon, carcinogenesis of the rectum, ulcerative colitis, an adenomatous polyp, familial polyposis and the like. A sulfate of UDCA also may be administered to inhibit or treat an inflammatory disorder of the liver. A UDCA sulfate may be used to improve serum biochemistries of liver disease or liver function, to increase bile flow or to decrease biliary secretion of phospholipid or cholesterol.
REFERENCES:
patent: 4565811 (1986-01-01), Di Schiena
patent: 5460812 (1995-10-01), Sipos
Goto, J., et al., "Synthesis of Monosulfates of Unconjugated and Conjugated Bile Acids", Chem. Pharm. Bull., vol. 27, pp. 1402-1411, 1979.
Czygan, P., et al., "Chenodeoxycholic acid but not ursodeoxycholic acid enhances colonic carcinogenesis in the rat", Falk Symposium 33, pp. 393-395, 1982.
Setchell, K.D.R., et al., "A Simple, Rapid and Non-Invasive Test of Compliance . . . Urinary Metabolite", AASLD Abstracts of Papers, No. 855, 1991.
Rigas, B., et al., "Ursodeoxycholic Acid and Piroxicam Up-Regulate MHC Antigen Expression in Rat Coloncytes During Colon Cancer Development", Gatrointestinal Oncology, A433, Apr., 1994.
Earnest, D. L., et al., "Chemoprevention of Azoxymethane-induced Colonic Carcinogenesis by Supplemental Dietary Ursodeoxycholic Acid", Cancer Research, pp. 5071-5074, Oct. 1, 1994.
Patent Cooperation Treaty International Search Report, PCT/US 96/18487, May 23, 1997.
Boll.Chim.Farm., vol. 126, No. 7, 1987, pp. 282-288, XP000644486, J.S. Franzone et al., "Attivita farmacologica dell'acido ursulocolico, forma solubile dell'UDCA".
Boll.Chim.Farm. vol. 126, No. 7, 1987, pp. 289-293, XP000644487, J.S. Franzone et al., "Farmacocinetica e metabolismo epatico dell'acido ursulcolico (forma solubile dell'UDCA) nel ratto".
Arzneimittelforschung, vol. 37, No. 8, Aug. 1987, pp. 983-987, XP000647307, N. Pacini et al., "Transformation of Sulfated Bile Acids by Human Intestinal Microflora".
Journal of Hepatology, vol. 15,m No. 1-2, May 1992, pp. 77-84, XP000645256, H. Takikawa et al., Effects of ursodeoxycholate, its glucuronide and disulfate and beta-muricholate on biliary bicarbonate concentration and biliary lipid excretion.
Journal of Hepatology, vol. 17, No.2, 1993, pp. 247-252, XP002030420, H. Takikawa et al., "Effects of organic anions and bile acids on biliary lipid excretion in hyperbilirubinemic mutant Sprague-Dawley rats".
Journal of Hepatology, vol. 17, No.2, Feb. 1993, pp. 241-246, XP000645240, N. Sano et al., "Estradiol-17beta-glucuronide-induced cholestasis".
Pharmaceutical Research, vol. 11, No. 5, May 1994 pp. 642-647, XP 000645007, A. Roda et al., "Improved Intestinal Absorption of an Enteric-Coated Sodium Ursodeoxycholate Formulation".
Children's Hospital Medical Center
Jarvis William R.A.
LandOfFree
Sulfate conjugates of ursodeoxycholic acid, and their beneficial does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfate conjugates of ursodeoxycholic acid, and their beneficial, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfate conjugates of ursodeoxycholic acid, and their beneficial will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2199297